Javascript must be enabled to continue!
Abstract 345: Characterizing and therapeutically targeting G-quadruplex DNA in ATRX-mutant glioma
View through CrossRef
Abstract
Inactivating ATRX mutations are defining molecular alterations in several cancer variants, including large subsets of malignant glioma. ATRX encodes a chromatin binding protein widely implicated in epigenetic and transcriptional regulation. However, ATRX is also thought to guard against genomic instability, in part by mitigating the formation of deleterious G-quadruplex (G4) DNA secondary structures. G4s have been shown to stall DNA replication leading to single-strand breaks and, potentially, DNA damage and genomic instability. To study this biology in a glioma-relevant context, we generated an isogenic astrocyte model featuring intact or deficient ATRX. While ATRX deficiency had no effect on baseline proliferation, cell cycle progression, and apoptosis, it led to markedly increased G4 formation, DNA damage, and replication stress signaling. These effects were reversed by ATRX re-expression. Moreover, ATRX-deficient astrocytes acquired copy number alterations over time, unlike ATRX-intact counterparts. Given these findings, we hypothesized that therapeutically targeting G4s might serve to exploit the inherent genomic vulnerabilities of ATRX-deficient cancer. Remarkably, treatment with a G4 stabilizing compound (CX3543) selectively inhibited growth and colony formation in ATRX-deficient astrocytes at nanomolar concentrations, and synergistically potentiated the effects of ionizing radiation and hydroxyurea. Finally, CX3543 significantly inhibited the growth of patient-derived, ATRX-deficient glioma xenografts in mice, with only minimal effects on ATRX-intact glioma xenografts. These results confirm and characterize a novel functionality for ATRX in the mitigation of genomic instability and point towards a viable strategy for therapeutically targeting ATRX deficiency in cancer.
Citation Format: Yuxiang Wang, Carla Danussi, Kasthuri Kannan, Timothy A. Chan, Jason T. Huse. Characterizing and therapeutically targeting G-quadruplex DNA in ATRX-mutant glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 345.
American Association for Cancer Research (AACR)
Title: Abstract 345: Characterizing and therapeutically targeting G-quadruplex DNA in ATRX-mutant glioma
Description:
Abstract
Inactivating ATRX mutations are defining molecular alterations in several cancer variants, including large subsets of malignant glioma.
ATRX encodes a chromatin binding protein widely implicated in epigenetic and transcriptional regulation.
However, ATRX is also thought to guard against genomic instability, in part by mitigating the formation of deleterious G-quadruplex (G4) DNA secondary structures.
G4s have been shown to stall DNA replication leading to single-strand breaks and, potentially, DNA damage and genomic instability.
To study this biology in a glioma-relevant context, we generated an isogenic astrocyte model featuring intact or deficient ATRX.
While ATRX deficiency had no effect on baseline proliferation, cell cycle progression, and apoptosis, it led to markedly increased G4 formation, DNA damage, and replication stress signaling.
These effects were reversed by ATRX re-expression.
Moreover, ATRX-deficient astrocytes acquired copy number alterations over time, unlike ATRX-intact counterparts.
Given these findings, we hypothesized that therapeutically targeting G4s might serve to exploit the inherent genomic vulnerabilities of ATRX-deficient cancer.
Remarkably, treatment with a G4 stabilizing compound (CX3543) selectively inhibited growth and colony formation in ATRX-deficient astrocytes at nanomolar concentrations, and synergistically potentiated the effects of ionizing radiation and hydroxyurea.
Finally, CX3543 significantly inhibited the growth of patient-derived, ATRX-deficient glioma xenografts in mice, with only minimal effects on ATRX-intact glioma xenografts.
These results confirm and characterize a novel functionality for ATRX in the mitigation of genomic instability and point towards a viable strategy for therapeutically targeting ATRX deficiency in cancer.
Citation Format: Yuxiang Wang, Carla Danussi, Kasthuri Kannan, Timothy A.
Chan, Jason T.
Huse.
Characterizing and therapeutically targeting G-quadruplex DNA in ATRX-mutant glioma [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL.
Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 345.
Related Results
CSIG-09. ATRX DEFICIENCY IN GLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE MICROENVIRONMENT IN VIVO
CSIG-09. ATRX DEFICIENCY IN GLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE MICROENVIRONMENT IN VIVO
Abstract
Current treatment for diffuse astrocytoma fails to address its underlying molecular mechanisms leading to inevitable disease progression and eventual patien...
Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma
Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma
ABSTRACTInactivating mutations inATRXcharacterize large subgroups of malignant gliomas in adults and children. ATRX deficiency in glioma induces widespread chromatin remodeling, dr...
GW-2974 and SCH-442416 modulators of tyrosine-kinase and adenosine receptors can also stabilize human telomeric G-quadruplex DNA: Insights into their anticancer effect
GW-2974 and SCH-442416 modulators of tyrosine-kinase and adenosine receptors can also stabilize human telomeric G-quadruplex DNA: Insights into their anticancer effect
Abstract
GW-2974 is a potent inhibitor for the tyrosine kinase receptor. It inhibits EGFR and ErbB-2 in tumor cells with high selectivity towards malignant over normal cell...
Arvo Meri Vanhan Vehmaan kihlakunnan pitäjien ja kylien nimet I
Arvo Meri Vanhan Vehmaan kihlakunnan pitäjien ja kylien nimet I
Kirja-arvioMeri, Arvo: Vanhan Vehmaan kihlakunnan pitäjien ja kylien nimet IKielenaineksetAhvenusjärvi (kieli: suomi, sivulla: 345)Haapasaari (kieli: suomi, sivulla: 342)haihtua (k...
IMMU-10. EXPLORING THE IMMUNOLOGIC CONSEQUENCES OF ATRX DEFICIENCY IN GLIOMA
IMMU-10. EXPLORING THE IMMUNOLOGIC CONSEQUENCES OF ATRX DEFICIENCY IN GLIOMA
Abstract
ATRX is a key chromatin regulator, which is mutated in large subsets of both adult and pediatric gliomas. Despite being a common mutation, little is known a...
GW-2974 and SCH-442416 modulators of tyrosine kinase and adenosine receptors can also stabilize human telomeric G-quadruplex DNA
GW-2974 and SCH-442416 modulators of tyrosine kinase and adenosine receptors can also stabilize human telomeric G-quadruplex DNA
GW-2974 is a potent tyrosine kinase receptor inhibitor while SCH-442416 is a potent adenosine receptors’ antagonist with high selectivity towards human adenosine A2Areceptor over o...
Rare dual‐genotype IDH mutant glioma: Review of previously reported cases and two new cases of true “oligoastrocytoma”
Rare dual‐genotype IDH mutant glioma: Review of previously reported cases and two new cases of true “oligoastrocytoma”
In 2016, the World Health Organization (WHO) eliminated “oligoastrocytoma” from the classification of central nervous system (CNS) tumors, in favor of an integrated histologic and ...
ID #304 Molecular hijacking of developmental master regulators through BRD4-driven super-enhancers in pediatric and AYA gliomas
ID #304 Molecular hijacking of developmental master regulators through BRD4-driven super-enhancers in pediatric and AYA gliomas
Abstract
Pediatric and adolescent/young adult (AYA) gliomas remain among the deadliest childhood cancers. Key subtypes include H3.3 G34R/V diffuse hemispheric gli...

